Purpose: To present effectiveness of intravitreal ranibizumab (IVR) injection for central serous chorioretinopathy (CSC), resistant to intravitreal bevacizumab (IVB) injection.
Methods: Files of the patients who had the diagnosis of CSC between 2005 and 2013 were reviewed retrospectively. Eighty-five eyes of 81 patients' files have been investigated. Ten eyes of 10 patients that were resistant to IVB, with no history of photodynamic therapy, were included in to this study. Demographic details, best-corrected visual acuity (BCVA), and central macular thickness (CMT) were studied to analyze the effectiveness of IVR.
Results: The mean age of the patients was 38.8 years (SD=4.7 years). The mean follow-up time after first IVR injection was 7.9 months (SD=1.5 months). The mean number of IVB and IVR injections was 2.0 (SD=0.7) and 1.3 (SD=0.4), respectively. The mean CMT before IVR injection was 392.4 μm (SD=66.3) and decreased to 194.1 μm (SD=9.3, P<0.001) at the last visit. The mean BCVA before IVR injection was 0.50 logMAR (SD=0.23) and improved to 0.05 logMAR (SD=0.06, P<0.001) at the last visit. In all cases after IVR injection, the subretinal fluid almost resolved completely, and leakage disappeared in fundus fluorescein angiography.
Conclusion: Ranibizumab might be a promising option for the patients with CSC, resistant to bevacizumab in acute or early chronic stage.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1089/jop.2014.0043 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Short-term fluctuation of intraocular pressure and influencing factors following intravitreal injection in patients with retinal vascular diseases.
Int J Ophthalmol
November 2024
Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Institute of Ophthalmology, Beijing Key Laboratory of Institute of Ophthalmology and Visual Sciences, Beijing 100730, China.
Aim: To investigate the patterns of short-term intraocular pressure (IOP) fluctuations and identify the contributing factors following intravitreal injection in patients with retinal vascular diseases.
Methods: Totally 81 patients were enrolled in this case control study. Eyes were categorized into 7 groups, including age-related macular degeneration (AMD), polypoidal choroidal vasculopathy (PCV), idiopathic choroidal neovascularization (CNV), proliferative diabetic retinopathy (PDR), diabetic macular edema (DME), macular edema secondary to branch (BVOME) and central (CVOME) retinal vein occlusion.
Factors predictive of early reactivation after ıntravitreal ranibizumab in agressive retinopathy of prematurity.
J Fr Ophtalmol
November 2024
Department of Ophthalmology, Baskent University Faculty of Medicine, Dadaloglu district, 2591, street, 4/A, Adana, 01250 Yuregir, Turkey.
Objective: Anti-VEGF agents are used in the treatment of aggressive retinopathy of prematurity (A-ROP), which is a rapidly progressive form of retinopathy of prematurity (ROP). This study aimed to evaluate risk factors for the early reactivation after anti-VEGF therapy with intravitreal ranibizumab (IVR) injection.
Methods: Consecutive cases of A-ROP were included in this retrospective study.
Baseline Choroidal Blood Flow Imbalance as a Predictive Factor for Macular Edema Recurrence Secondary to Branch Retinal Vein Occlusion.
Diagnostics (Basel)
October 2024
Department of Ophthalmology, Toho University Sakura Medical Center, 564-1, Shimoshizu, Sakura 285-8741, Japan.
Article Synopsis
- This study assesses how choroidal blood flow (CBF) and choroidal thickness (CT) can predict if macular edema will return in patients with a specific type of eye condition (BRVO) after receiving treatment.
- Sixteen patients were treated with an injection and monitored for changes in CBF and CT over a year using specialized imaging techniques.
- Results showed that thicker CT in affected areas initially dropped after one week, while CBF remained steady; however, an imbalance in CBF was linked to how many injections were later needed, suggesting it could help predict recurrence of macular edema.
Real-life neovascular AMD treatment considering reimbursement in Turkiye: One-year comparison of switching to intravitreal ranibizumab or aflibercept after treatment failure with three loading intravitreal bevacizumab injections.
North Clin Istanb
October 2024
Department of Ophthalmology, Marmara University Faculty of Medicine, Istanbul, Turkiye.
Objective: To compare one-year anatomical and functional results of switching to an on-label intravitreal anti-vascular endothelial growth factor (anti-VEGF) agent (intravitreal ranibizumab [IVR] or aflibercept [IVA]) after treatment failure with three loading doses of off-label intravitreal bevacizumab (IVB), which is mandatory in the treatment of neovascular age-related macular degeneration (nAMD) to get reimbursement from Social Security Institution in Turkiye.
Methods: This comparative, real-life, retrospective cohort study included treatment-naïve nAMD patients treated starting with three loading doses of IVB, switched to three loading doses of IVR and IVA due to treatment failure after IVB loading, and followed up one year with a treat-and-extend (T&E) protocol with 2-week extension/shortening intervals. The primary outcomes were changes in best-corrected visual acuity (BCVA; logMAR) and central macular thickness (CMT, µm) one year after the switch, and the secondary outcomes were maximum treatment intervals, number of injections, and disease activity rates.
Efficacy and Safety of Aflibercept and Ranibizumab in the Treatment of Retinopathy of Prematurity.
Clin Ther
October 2024
Department of Neonatal Pediatrics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. Electronic address:
Purpose: To compare the efficacy, recurrence rate, and recurrence interval of intravitreal injection of aflibercept (IVA) and ranibizumab (IVR) in patients with retinopathy of prematurity (ROP).
Methods: This is a single-center retrospective study of neonates hospitalized from January 2018 to March 2023 in the Department of Neonatology of the First Affiliated Hospital of Zhengzhou University who received intravitreal injection of anti-vascular endothelial growth factor owing to type 1 prethreshold ROP, threshold ROP, or aggressive posterior ROP. Clinical data were collected to record the cure, recurrence, number of injections, and side effects of ROP.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!